➡️ The evolving paradigm of therapy in T-cell ALL by @NitinJainMD at US AML/ALL focus meet @_MDEducation ✅ Bcl2/BclXL inhibitors ✅ CD 7 CAR-Ts ✅ LCK inhibition by Dasatinib/Ponatinib https://t.co/btUp5uOKaW (@jayastuMD)

👉👉 Excited to share that our trial of ponatinib (as LCK inhibitor) + VEN + mini-CVD for R/R T-ALL is now open 👉Joint collaboration MDACC and St Jude @Junjyang @jiyang_yu showed 40% T-ALL overexpress LCK and sensitive to ponatinib/dasatinib (Notably, none had ABL fusion) 1/2 (@NitinJainMD)

No clinically relevant activity of the oral tyrosine kinase inhibitor nintedanib, a drug targeting PDGFR A/B, FGFR 1-3 and FLT 3, in patients with soft tissue sarcoma after first line anthracycline-based chemotherapy. See https://t.co/v4OhqhtQeS (@schoffski)

Certainly need to be explore! Clinical trials design for SCLC must be updated. Several case reports are giving insights of #PrecisionMedicine in SCLC like our experience Remarkable Activity Pazopanib in Refractory FGFR1-Amplified ED-SCLC https://t.co/VLY8Hlm2Ov @isliquidbiopsy https://t.co/3Q3ZJIirjW (@ChristianRolfo)

#ASCO20 The RAMES study was a phase II trial of 2nd line gemcitabine +/- ramucirumab for pleural mesothelioma (#MPM). VEGF is an enticing target. MAPS showed adding bev to cis/pem improved OS (not FDA approved) though LUME-meso (nintedanib + cis/pem) was negative. #OncoAlert (@StephenVLiu)